A new approach to antiplatelet therapy: inhibitor of GPIb/V/IX-vWF interaction.
Evidence has been presented that the interaction between von Willebrand factor (vWF) and its platelet membrane receptor, the GPIb/V/IX complex, plays an important role in the pathogenesis of arterial thrombosis. A monoclonal antibody against the A1 domain of vWF has been shown to inhibit thrombus formation in the animal model of arterial thrombosis. Based upon these findings, a new approach to treating arterial thrombosis has been proposed by intervening in the interaction between vWF and platelet.
Ikeda
Y
Y
Department of Internal Medicine and Blood Center, Keio University School of Medicine, Tokyo, Japan. yikeda@med.keio.au.jp
Handa
M
M
Murata
M
M
Goto
S
S
D000085:Acetates / Q000627:therapeutic use; D000244:Adenosine Diphosphate / Q000494:pharmacology; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D003094:Collagen / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D004837:Epinephrine / Q000494:pharmacology; D000939:Epitopes / Q000276:immunology; D020022:Genetic Predisposition to Disease; D006168:Guinea Pigs; D018056:Hemorheology; D006801:Humans; D016023:Integrins / Q000235:genetics / Q000378:metabolism; D008081:Liposomes; D046911:Macromolecular Substances; D009203:Myocardial Infarction / Q000097:blood; D010973:Platelet Adhesiveness / Q000187:drug effects / Q000502:physiology; D010974:Platelet Aggregation / Q000187:drug effects* / Q000502:physiology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D019038:Platelet Glycoprotein GPIb-IX Complex / Q000037:antagonists & inhibitors* / Q000235:genetics; D011110:Polymorphism, Genetic; D038981:Receptors, Collagen; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D013314:Stress, Mechanical; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014841:von Willebrand Factor / Q000037:antagonists & inhibitors* / Q000276:immunology
D000085:Acetates; D000911:Antibodies, Monoclonal; D000939:Epitopes; D016023:Integrins; D008081:Liposomes; D046911:Macromolecular Substances; D010975:Platelet Aggregation Inhibitors; D019038:Platelet Glycoprotein GPIb-IX Complex; D038981:Receptors, Collagen; D011993:Recombinant Fusion Proteins; D014841:von Willebrand Factor; D014443:Tyrosine; D000244:Adenosine Diphosphate; D003094:Collagen; C084062:lamifiban; D004837:Epinephrine